Mechanisms of chemotherapy resistance in ovarian cancer

Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (...

Full description

Saved in:
Bibliographic Details
Published inCancer drug resistance Vol. 5; no. 2; pp. 304 - 316
Main Authors Ortiz, Mylena, Wabel, Emma, Mitchell, Kerry, Horibata, Sachi
Format Journal Article
LanguageEnglish
Published OAE Publishing Inc 01.01.2022
Subjects
Review
Online AccessGet full text

Cover

More Information
Summary:Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Academic Editor: Godefridus J. (Frits) Peters | Copy Editor: Jia-Xin Zhang | Production Editor: Jia-Xin Zhang
ISSN:2578-532X
2578-532X
DOI:10.20517/cdr.2021.147